Throughout 2025, drugmakers of all stripes have collectively poured billions of dollars into U.S. manufacturing investments. Many of those projects have centered on later stages of the production ...

France’s Saint‑Julien site adds a bioprocess development suite for upstream/downstream scale-up of recombinant proteins, ...

LGM Pharma, a leading provider of tailored API sourcing, contract analytical testing, and CDMO services for the full drug ...

Axplora, a German CDMO that specializes in specialty active pharmaceutical ingredients for small molecules and antibody-drug ...

EAST RUTHERFORD, N.J., Oct. 22, 2025 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced a $120 million investment to expand its U.S.

While the United Kingdom feted President Trump in his second state visit, GSK said Wednesday it will spend $30 billion over the next five years to build new manufacturing and research facilities ...

EAST RUTHERFORD, N.J., March 23, 2026 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing ...

Cambrex is expanding US and European operations with major investments in Iowa and Milan, boosting API capacity and R and D ...

Wilmington PharmaTech ("Wilmington"), a leading U.S.-based research, development, and manufacturing organization (CRDMO) focused on complex custom small-molecule API production, today announced a $50 ...

The expanded infrastructure features a new block to enhance existing CRDMO capabilities supported by dedicated peptide manufacturing capacity across two additional specialized units.

Fujifilm Biotechnologies will open a new biologics manufacturing plant in the U.S. this fall, with Regeneron and Johnson & Johnson as the initial customers. The Holly Springs, North Carolina, site is ...

BRIDGEWATER, N.J. & NEW YORK--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”), a global pharmaceutical company, and ...